Turbine Raises $25M Series B and Expands into Immunology with Pharma Partnership

Turbine has raised $25 million in Series B funding led by Interactive Venture Partners, with participation from Beiersdorf Venture Capital and existing investors, announced in a press release. The financing will support expansion of Turbine’s AI-driven virtual cell platform and the launch of its first immunology-focused partnership with a top 10 pharmaceutical company.

The funding round will enable Turbine to extend its platform to virtualize new assays across discovery and translational medicine. The company's Virtual Lab allows researchers to run large-scale virtual experiments integrated into pharmaceutical workflows. Beiersdorf Venture Capital stated that the investment aligns with its interest in deep-tech approaches for skin biology and safety research.

Turbine’s new collaboration in immunology will use proprietary datasets from its partner to train virtual assays that model immune cell behavior. The goal is to generate mechanistic insights into immune pathways and identify new therapeutic combinations. The company has previously worked with major biopharma partners including MSD, AstraZeneca, and Bayer.